SCHEMBL28576192

SCHEMBL28576192

COC(=O)CNC1(CN)CCCCC1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.39
LMNA P02545 2/20 0.39
USP2 O75604 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP1A2 P05177 1/20 0.39
BLM P54132 1/20 0.39
CACNA2D1 P54289 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
DPP4 P27487 6/20 0.37
CYP3A4 P08684 2/20 0.37
EPHX2 P34913 1/20 0.37
HSD17B10 Q99714 1/20 0.34
TET2 Q6N021 1/20 0.33
KDM4E B2RXH2 1/20 0.32
RECQL P46063 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28873044 0.85 GAA (0.39) TSHRLMNAUSP2ALDH1A1CYP1A2
SCHEMBL25857189 0.84 DPP4 (0.38) TSHRDPP4CYP3A4EPHX2HSD17B10
SCHEMBL21752029 0.79 TSHR (0.47) TSHRLMNAUSP2ALDH1A1CYP1A2
SCHEMBL23513339 0.79 DPP4 (0.35) TSHRDPP4CYP3A4EPHX2HSD17B10
SCHEMBL17125039 0.78 TSHR (0.36) TSHRDPP4CYP3A4EPHX2HSD17B10
SCHEMBL15620816 0.78 TSHR (0.36) TSHRDPP4CYP3A4EPHX2HSD17B10
SCHEMBL28815502 0.78 ALDH1A1 (0.38) TSHRLMNAUSP2ALDH1A1CYP1A2
SCHEMBL23513275 0.77 DPP4 (0.34) TSHRDPP4CYP3A4EPHX2HSD17B10
Bromide SCHEMBL28562616 0.76 DPP4 (0.33) TSHRDPP4CYP3A4EPHX2HSD17B10
SCHEMBL4159695 0.73 CYP3A4 (0.40) TSHRALDH1A1CYP3A4EPHX2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12264135-B2 Synthesis of 1,4-diazaspiro[5.5]undecan-3-one PHARMACOSMOS HOLDING A/S (DK) 2025-04-01 US disclosed
US-20240199556-A1 Synthesis of 1,4-Diazaspiro[5.5]Undecan-3-One G1 THERAPEUTICS, INC. (US) 2024-06-20 US disclosed
US-11708337-B2 Synthesis of 1,4-diazaspiro[5.5]undecan-3-one G1 THERAPEUTICS, INC. (US) 2023-07-25 US disclosed
CN-112839657-A Improved synthesis of 1, 4-diazaspiro [5.5] undecan-3-ones G1治疗公司 2021-05-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12264135-B2 Synthesis of 1,4-diazaspiro[5.5]undecan-3-one NDC1, SDC1, SDC2 TSHR 3147/4885LMNA 419/4885USP2 1000/4885
US-11708337-B2 Synthesis of 1,4-diazaspiro[5.5]undecan-3-one NDC1, SDC1, SDC2 TSHR 3147/4885LMNA 419/4885USP2 1000/4885
US-20240199556-A1 Synthesis of 1,4-Diazaspiro[5.5]Undecan-3-One NDC1, SDC1, SDC2 TSHR 3147/4885LMNA 419/4885USP2 1000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.